<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_raon-2019-0009_s_005">
<h3>Background</h3>
<p>Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1 (<italic>AQP1</italic>) genetic polymorphisms influence the risk of MM and the response to cisplatin based MM treatment.</p></sec>
<sec id="j_raon-2019-0009_s_006">
<h3>Patients and methods</h3>
<p>The case-control study included 231 patients with MM and a control group of 316 healthy blood donors. All subjects were genotyped for three <italic>AQP1</italic>polymorphisms (rs1049305, rs1476597 and rs28362731). Logistic and Cox regression were used in statistical analysis.</p></sec>
<sec id="j_raon-2019-0009_s_007">
<h3>Results</h3>
<p><italic>AQP1</italic> rs1049305 polymorphism was significantly associated with MM risk in dominant model adjusted for gender and age (OR = 0.60, 95% CI = 0.37–0.96, P<sub>adj</sub> = 0.033). This polymorphism was also significantly associated with cisplatin based treatment related anaemia (unadjusted: OR = 0.49, 95% CI = 0.27–0.90, P = 0.021; adjusted: for CRP: OR = 0.52, 95% CI = 0.27–0.99, P = 0.046), with leukopenia (OR = 2.09, 95% CI = 1.00–4.35, P = 0.049) in dominant model and with thrombocytopenia (OR = 3.06, 95% CI = 1.01–9.28, P = 0.048) and alopecia (OR = 2.92, 95% CI = 1.00–8.46, P = 0.049) in additive model. <italic>AQP1</italic> rs28362731 was significantly associated with thrombocytopenia (unadjusted: OR = 3.73, 95% CI = 1.00–13.84, P = 0.049; adjusted for pain: OR = 4.63, 95% CI = 1.13–19.05, P = 0.034) in additive model.</p></sec>
<sec id="j_raon-2019-0009_s_008">
<h3>Conclusions</h3>
<p><italic>AQP1</italic> may play a role in the risk of MM. Furthermore, <italic>AQP1</italic> genotype information could improve the prediction of MM patients at increased risk for cisplatin toxicity.</p></sec></abstract>

Background
Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1 (AQP1) genetic polymorphisms influence the risk of MM and the response to cisplatin based MM treatment.

Patients and methods
The case-control study included 231 patients with MM and a control group of 316 healthy blood donors. All subjects were genotyped for three AQP1polymorphisms (rs1049305, rs1476597 and rs28362731). Logistic and Cox regression were used in statistical analysis.

Results
AQP1 rs1049305 polymorphism was significantly associated with MM risk in dominant model adjusted for gender and age (OR = 0.60, 95% CI = 0.37–0.96, Padj = 0.033). This polymorphism was also significantly associated with cisplatin based treatment related anaemia (unadjusted: OR = 0.49, 95% CI = 0.27–0.90, P = 0.021; adjusted: for CRP: OR = 0.52, 95% CI = 0.27–0.99, P = 0.046), with leukopenia (OR = 2.09, 95% CI = 1.00–4.35, P = 0.049) in dominant model and with thrombocytopenia (OR = 3.06, 95% CI = 1.01–9.28, P = 0.048) and alopecia (OR = 2.92, 95% CI = 1.00–8.46, P = 0.049) in additive model. AQP1 rs28362731 was significantly associated with thrombocytopenia (unadjusted: OR = 3.73, 95% CI = 1.00–13.84, P = 0.049; adjusted for pain: OR = 4.63, 95% CI = 1.13–19.05, P = 0.034) in additive model.

Conclusions
AQP1 may play a role in the risk of MM. Furthermore, AQP1 genotype information could improve the prediction of MM patients at increased risk for cisplatin toxicity.

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Background
Malignant mesothelioma (MM) is an asbestos related aggressive tumor with poor prognosis. The aim of this study was to investigate if aquaporin 1...

Genetic polymorphisms in aquaporin 1 as risk factors for malignant mesothelioma and biomarkers of response to cisplatin treatment

Article Category: Research Article

Online veröffentlicht: 03. März 2019

Seitenbereich: 96 - 104

Eingereicht: 09. Jan. 2019

Akzeptiert: 25. Jan. 2019

DOI: https://doi.org/10.2478/raon-2019-0009

© 2019 Barbara Senk, Katja Goricar, Viljem Kovac, Vita Dolzan, Alenka Franko, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.